Dyne Therapeutics press release (DYN): Q1 GAAP EPS of -$0.73 beats by $0.04. - Cash, cash equivalents and marketable securities were $972.2 million as of March 31, 2026. The Company continues to expect that its cash, cash equivalents and marketable securities as of March 3
Dyne Therapeutics press release (DYN): Q1 GAAP EPS of -$0.73 beats by $0.04. – Cash, cash equivalents and marketable securities were $972.2 million as of March 31, 2026.
The Company continues to expect that its cash, cash equivalents and marketable securities as of March 31, 2026, will be
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.
